Full text is available at the source.
Abstract
Emerging molecular biomarkers may enable early detection and targeted prevention of age-related hearing loss (ARHL).
- Traditional audiometry fails to detect molecular deterioration that occurs before clinical hearing decline.
- Core pathological axes evaluated include cellular aging, inner ear cell death, chronic inflammation, oxidative stress, and genetic differences.
- Preclinical evidence suggests that these molecular signatures could serve as actionable targets for personalized treatments.
- Potential interventions may include novel anti-inflammatory, antioxidant, and gene therapies.
- A theoretical framework for precision diagnostics could integrate genomic, inflammatory, and oxidative profiles.
- Current findings are primarily based on mechanistic and preclinical studies, necessitating further validation in human clinical settings.
Simplified